Search research articles
Contact Us
Filters
Showing results (171-180 of 224) with videos related to
Page
of 23
Sort By:
JAMA
|
November 18, 2011
Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease
Jessica L Mega, Willibald Hochholzer, Andrew L Frelinger, et al.
JAMA Cardiology
|
September 1, 2025
Safety of Factor XI Inhibition With Abelacimab in Atrial Fibrillation by Kidney Function: A Prespecified Analysis of the AZALEA-TIMI 71 Randomized Clinical Trial
Siddharth M Patel, Robert P Giugliano, David A Morrow, et al.
The Lancet. Diabetes & Endocrinology
|
November 28, 2024
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials
Sunil V Badve, Anika Bilal, Matthew M Y Lee, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology
|
October 28, 2021
LEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery Disease
Christian T Ruff, Michael J Koren, Joseph Grimsby, et al.
JAMA Cardiology
|
December 28, 2022
Predictive Utility of a Coronary Artery Disease Polygenic Risk Score in Primary Prevention
Nicholas A Marston, James P Pirruccello, Giorgio E M Melloni, et al.
American Heart Journal
|
December 9, 2020
Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) Investigators
Anthony P Carnicelli, Hwanhee Hong, Robert P Giugliano, et al.
Journal of the American College of Cardiology
|
September 4, 2024
Heart Failure Risk Assessment Using Biomarkers in Patients With Atrial Fibrillation: Analysis From COMBINE-AF
Paul M Haller, Petr Jarolim, Michael G Palazzolo, et al.
The American Journal of Medicine
|
May 5, 2020
Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative
Ebrahim Barkoudah, Gregory Piazza, Todd E H Hecht, et al.
Circulation
|
June 23, 2025
Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial
Samer Al Said, Siddharth M Patel, Robert P Giugliano, et al.
JAMA Cardiology
|
February 4, 2026
Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-TIMI 71 Trial
Samer Al Said, Siddharth M Patel, Robert P Giugliano, et al.
Page
of 23
Search research articles
Search
Showing results (171-180 of 224) with videos related to
Sort By:
Page
of 23
JAMA
|
November 18, 2011
Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease
Jessica L Mega, Willibald Hochholzer, Andrew L Frelinger, et al.
JAMA Cardiology
|
September 1, 2025
Safety of Factor XI Inhibition With Abelacimab in Atrial Fibrillation by Kidney Function: A Prespecified Analysis of the AZALEA-TIMI 71 Randomized Clinical Trial
Siddharth M Patel, Robert P Giugliano, David A Morrow, et al.
The Lancet. Diabetes & Endocrinology
|
November 28, 2024
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials
Sunil V Badve, Anika Bilal, Matthew M Y Lee, et al.
Arteriosclerosis, Thrombosis, and Vascular Biology
|
October 28, 2021
LEGACY: Phase 2a Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamic Effects of the Anti-EL (Endothelial Lipase) Antibody MEDI5884 in Patients With Stable Coronary Artery Disease
Christian T Ruff, Michael J Koren, Joseph Grimsby, et al.
JAMA Cardiology
|
December 28, 2022
Predictive Utility of a Coronary Artery Disease Polygenic Risk Score in Primary Prevention
Nicholas A Marston, James P Pirruccello, Giorgio E M Melloni, et al.
American Heart Journal
|
December 9, 2020
Individual Patient Data from the Pivotal Randomized Controlled Trials of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation (COMBINE AF): Design and Rationale: From the COMBINE AF (A Collaboration between Multiple institutions to Better Investigate Non-vitamin K antagonist oral anticoagulant use in Atrial Fibrillation) Investigators
Anthony P Carnicelli, Hwanhee Hong, Robert P Giugliano, et al.
Journal of the American College of Cardiology
|
September 4, 2024
Heart Failure Risk Assessment Using Biomarkers in Patients With Atrial Fibrillation: Analysis From COMBINE-AF
Paul M Haller, Petr Jarolim, Michael G Palazzolo, et al.
The American Journal of Medicine
|
May 5, 2020
Extended Venous Thromboembolism Prophylaxis in Medically Ill Patients: An NATF Anticoagulation Action Initiative
Ebrahim Barkoudah, Gregory Piazza, Todd E H Hecht, et al.
Circulation
|
June 23, 2025
Abelacimab Versus Rivaroxaban in Patients With Atrial Fibrillation on Antiplatelet Therapy: A Prespecified Analysis of the AZALEA-TIMI 71 Trial
Samer Al Said, Siddharth M Patel, Robert P Giugliano, et al.
JAMA Cardiology
|
February 4, 2026
Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-TIMI 71 Trial
Samer Al Said, Siddharth M Patel, Robert P Giugliano, et al.
Page
of 23